Union Bancaire Privee UBP SA bought a new stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 5,485 shares of the financial services provider’s stock, valued at approximately $693,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IBB. Darwin Wealth Management LLC acquired a new stake in shares of iShares Biotechnology ETF in the third quarter valued at $29,000. Highline Wealth Partners LLC purchased a new stake in shares of iShares Biotechnology ETF in the 3rd quarter valued at $30,000. HHM Wealth Advisors LLC raised its holdings in shares of iShares Biotechnology ETF by 200.0% in the 4th quarter. HHM Wealth Advisors LLC now owns 225 shares of the financial services provider’s stock valued at $30,000 after buying an additional 150 shares during the period. Ashton Thomas Securities LLC purchased a new stake in shares of iShares Biotechnology ETF in the 3rd quarter valued at $36,000. Finally, Newbridge Financial Services Group Inc. purchased a new stake in shares of iShares Biotechnology ETF in the 4th quarter valued at $33,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.
iShares Biotechnology ETF Trading Down 0.1 %
IBB stock opened at $138.74 on Tuesday. iShares Biotechnology ETF has a 12-month low of $123.60 and a 12-month high of $150.57. The business’s fifty day moving average price is $135.64 and its 200 day moving average price is $140.77.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Read More
- Five stocks we like better than iShares Biotechnology ETF
- What Are Dividend Champions? How to Invest in the Champions
- Finding Hidden Gems: Unconventional Penny Stock Investing
- How to Read Stock Charts for Beginners
- Price Targets on NVIDIA Rise in Front of Earnings
- Golden Cross Stocks: Pattern, Examples and Charts
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.